Thoracic and Gastrointestinal Malignancies Branch Clinical Core

医学TGMB有一个强大的临床项目，用于治疗标准治疗失败的晚期胸部和胃肠道癌症患者。胸科团队正在为非小细胞肺癌、小细胞肺癌、恶性间皮瘤和胸腺癌患者进行创新研究。其中包括使用NCI科学家开发的新疗法。我们团队的一个主要重点是开发靶向肿瘤抗原的药物，在许多癌症中高度表达的间皮素。我们正在使用免疫毒素- lmb -100，抗体药物偶联物-BAY 94-9343，钍-227标记的抗体螯合剂偶联物-BAY 2287411和靶向CAR-T细胞的间皮素来治疗这些癌症。此外，我们正在进行包括免疫检查点抑制剂在内的免疫治疗药物的临床试验，以治疗标准治疗失败的胸部癌症患者。TGMB也在进行胃肠道癌症的治疗研究，特别强调肝癌和胰腺癌。TGMB的研究人员已经建立了一个强大的肝癌治疗方案，包括使用免疫治疗药物单独或联合放射治疗或局部消融治疗肝癌。胃肠道组也在进行治疗胰腺癌的新药的临床试验。

The medical TGMB has a robust clinical program for treatment of patients with advanced thoracic and GI cancers who have failed standard therapies. The thoracic team is conducting innovative studies for patients with non-small cell lung cancer, small cell lung cancer, malignant mesothelioma and thymic cancers. These include use of novel treatments developed by scientists at the NCI. A major focus of our team is the development of drugs targeting the tumor antigen, mesothelin that is highly expressed in many cancers. We are using an immunotoxin -LMB-100, an antibody drug conjugate- BAY 94-9343, thorium-227 labeled antibody-chelator conjugate-BAY 2287411 and mesothelin targeting CAR-T cells to treat these cancers. In addition, we are conducting clinical trials using immunotherapy agents including immune checkpoint inhibitors to treat patients with thoracic cancers who have failed standard treatments. The TGMB is also conducting studies for treatment of gastrointestinal cancers with a special emphasis on liver and pancreatic cancer. Investigators within the TGMB have established a robust program for treatment of patients with liver cancer including use of immunotherapy agents either alone or in combination with radiation therapy or locally ablative therapies for liver cancer. The gastrointestinal group is also conducting clinical trials of novel agents for treatment of pancreatic cancer.